drugset / Trial / NCT03878264

Absolute Bioavailability and Metabolism Study of CORT118335 in Healthy Male Participants

NCT03878264

Phase 1 Completed 12 enrolled Corcept Therapeutics
Non-randomizedSequentialOpen-labelBasic science

Summary

This study will evaluate the absolute bioavailability of CORT118335 and determine the mass balance recovery, absorption, metabolism and elimination, and metabolite profile and identification of metabolite structures following a single oral dose of CORT118335 in healthy male participants.

Timeline

Start
2018-08-06
Primary completion
2019-03-24
Completion
2019-03-24

Drugs

EvaluationDrugModalityDoseRoute
Subject Miricorilant Small molecule 100 ug Oral
Subject Miricorilant Small molecule 150 mg Oral
Subject Miricorilant Small molecule 900 mg Oral

Indications

No indication recorded.